---
figid: PMC4583193__nihms442420f1
figtitle: Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
pmcid: PMC4583193
filename: nihms442420f1.jpg
figlink: /pmc/articles/PMC4583193/figure/F1/
number: F1
caption: Binding of hepatocyte growth factor (HGF) to c-MET, homodimerization, and
  autophosphorylation (denoted by orange circles containing “P”) elicit downstream
  signaling mediated by adaptor proteins (Gab1 and Grb2) to induce activation of the
  phosphotidylinositol-3 kinase (PI3K), Ras/Raf/MEK/ERK, and the Cdc42/Rac1 pathways.
  HGF-independent signaling can be mediated by phosphorylated epidermal growth factor
  receptor (EGFR), which can be activated by its ligand transforming growth factor
  alpha (TGFα). Inhibitors of the HGF/c-MET signaling pathway are shown in yellow
  boxes with their corresponding targets denoted. Inhibitors in bold have completed
  phase II trials in advanced HCC.
papertitle: Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma.
reftext: Lipika Goyal, et al. Clin Cancer Res. ;19(9):2310-2318.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9630281
figid_alias: PMC4583193__F1
figtype: Figure
redirect_from: /figures/PMC4583193__F1
ndex: 4f6eafe5-decc-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4583193__nihms442420f1.html
  '@type': Dataset
  description: Binding of hepatocyte growth factor (HGF) to c-MET, homodimerization,
    and autophosphorylation (denoted by orange circles containing “P”) elicit downstream
    signaling mediated by adaptor proteins (Gab1 and Grb2) to induce activation of
    the phosphotidylinositol-3 kinase (PI3K), Ras/Raf/MEK/ERK, and the Cdc42/Rac1
    pathways. HGF-independent signaling can be mediated by phosphorylated epidermal
    growth factor receptor (EGFR), which can be activated by its ligand transforming
    growth factor alpha (TGFα). Inhibitors of the HGF/c-MET signaling pathway are
    shown in yellow boxes with their corresponding targets denoted. Inhibitors in
    bold have completed phase II trials in advanced HCC.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tgfa
  - Hgf
  - Met
  - Egf
  - Gab1
  - Grb2
  - Emd
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Pik3r1
  - Mdk
  - Akt1
  - Ephb2
  - Mapk1
  - Cdc42
  - Mtor
  - Rac1
  - TGFA
  - HGF
  - IL6
  - SOS1
  - MET
  - EGF
  - GAB1
  - PIGU
  - GRB2
  - EMD
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - CDC42
  - MTOR
  - RAC1
  - RNASE1
  - Pik3cg
  - Ephb1
  - Rnase1l1
  - Egfr
  - mab
  - dos
  - drk
  - Orai
  - Ras64B
  - Ras85D
  - Raf
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Dsor1
  - Mtk
  - Akt
  - Erk7
  - rl
  - Tor
  - Rac2
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Foretinib
  - Tivantinib
  - XL184
  - Cabozantinib
  - Met
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
